Liraglutide to Dulaglutide Dose Conversion Guide
Medically reviewed by Lauren Okafor | MD, The Frank H Netter MD School of Medicine, Loyola University Medical Center on July 21st, 2026.
Published on July 22nd, 2026. Updated on July 22nd, 2026.
Key takeaways
No exact milligram-to-milligram conversion exists between liraglutide and dulaglutide; clinical judgment guides every switch.
Most patients begin dulaglutide at the lowest available dose of 0.75 mg weekly, regardless of their prior liraglutide dose.
GI side effects like nausea and diarrhea are common during the transition and are usually temporary, not a sign that dulaglutide is the wrong medication.
Blood glucose may fluctuate in the first one to two weeks after switching, so more frequent monitoring is recommended during that window.
A provider or AI consultation should be part of any GLP-1 medication switch, not just a comparison of package insert labels.
Why Patients Consider Switching from Liraglutide to Dulaglutide
Liraglutide, sold under the brand name Victoza, has been a widely used treatment for type 2 diabetes for over a decade. It is injected once daily, and while effective, that daily schedule can become a barrier to consistent use for some patients. Dulaglutide, known by the brand name Trulicity, offers the same class of medication but in a once-weekly injection, which many people find easier to maintain over time.
Beyond convenience, insurance formulary changes, out-of-pocket costs, and individual side effect profiles all play a role in why a prescriber might recommend this switch. Both drugs belong to the GLP-1 receptor agonist class, meaning they stimulate insulin release in a glucose-dependent way and help slow gastric emptying. However, their molecular structures, half-lives, and dosing frequencies differ enough that moving from one to the other is not as simple as swapping one brand for another.
Understanding how the transition works, and what to realistically expect, helps patients feel more confident and prepared before their first dulaglutide dose.
How Liraglutide and Dulaglutide Compare
Despite sharing the same mechanism of action, liraglutide and dulaglutide are pharmacologically distinct in several important ways. Liraglutide is dosed daily in amounts ranging from 0.6 mg to 1.8 mg, with 1.8 mg being the maximum approved dose for diabetes management. Dulaglutide is dosed weekly, with approved doses ranging from 0.75 mg to 4.5 mg.
The difference in dosing intervals reflects differences in how each drug is structured and how long it remains active in the body. Liraglutide has a half-life of roughly 13 hours, while dulaglutide's half-life extends to approximately five days, which is what allows for weekly dosing.
In terms of clinical outcomes, both medications produce broadly comparable reductions in A1C and body weight at their respective therapeutic doses. However, individual patient response varies, and the right dose for any given person after a switch depends on ongoing glucose monitoring and provider assessment rather than a calculation done in advance.
The Conversion Framework Used in Clinical Practice
One of the most important things to understand about switching these two medications is that no FDA-approved conversion table exists. There is no official formula that says a specific daily liraglutide dose equals a specific weekly dulaglutide dose. This is because the two drugs differ in potency, delivery, and pharmacokinetics in ways that make a simple milligram comparison misleading.
In clinical practice, the standard approach is conservative. Most prescribers start dulaglutide at the lowest available dose of 0.75 mg weekly, regardless of what dose of liraglutide the patient was taking. This cautious starting point allows the body to adjust to the new medication, reduces the likelihood of gastrointestinal side effects, and gives the care team a baseline from which to titrate upward safely.
Patients who were on liraglutide 1.8 mg daily, the maximum dose, may sometimes begin dulaglutide at 1.5 mg weekly after tolerability has been confirmed, but this decision is individualized. Dose escalation to 3.0 mg or 4.5 mg weekly happens gradually over weeks to months, guided by A1C results, fasting glucose levels, and how well the patient tolerates each dose level.
The table below summarizes the approximate dose mapping used in clinical practice:
Liraglutide Dose (mg/day) |
Suggested Starting Dulaglutide Dose (mg/week) |
Titration Guidance |
|---|---|---|
0.6 mg (initial titration dose) |
0.75 mg |
Standard starting dose; assess tolerability at 4 weeks |
1.2 mg (common maintenance dose) |
0.75 mg |
Titrate to 1.5 mg after 4 weeks if tolerated and glycemic goals unmet |
1.8 mg (maximum dose) |
0.75 to 1.5 mg |
May start at 1.5 mg if prior tolerability is well established; escalate to 3.0 mg or 4.5 mg as needed |
These are approximate clinical guidelines, not a substitute for individualized prescriber direction.
What to Expect During the Transition Period
The transition from liraglutide to dulaglutide does not typically require a washout period. Because both drugs act on the same receptor, stopping liraglutide and beginning dulaglutide the same day or the following day is the standard practice. There is no clinical benefit to leaving a gap between the two medications, and doing so may cause unnecessary blood glucose fluctuations.
That said, some degree of adjustment is normal. GI side effects including nausea, loose stools, and reduced appetite may temporarily increase in the first few weeks as the body adapts to the new agent. These effects are common to the entire GLP-1 drug class and usually ease on their own as the body adjusts. They are not generally a sign that dulaglutide is the wrong choice.
Blood glucose levels may also shift modestly during the first one to two weeks. Patients are encouraged to monitor more frequently during this window so that any significant changes can be identified and addressed before they become a bigger concern. Keeping a simple log of morning fasting glucose readings can be especially helpful to share at follow-up appointments.
When Provider Oversight Matters Most
While the switch from liraglutide to dulaglutide is generally well tolerated, certain health conditions make prescriber review especially important before making any change. Patients with chronic kidney disease, a history of pancreatitis, or personal or family history of medullary thyroid carcinoma should have a thorough clinical assessment before switching GLP-1 agents.
Any dose escalation beyond 1.5 mg of dulaglutide weekly should be based on real glycemic data, including A1C values and fasting glucose patterns, and should be supervised by a qualified provider. Self-adjusting doses based on how a patient feels, or based on what someone else in a similar situation is taking, is not a safe approach.
Doctronic, the first AI legally authorized to practice medicine in the United States, offers free AI consultations 24 hours a day for patients who want to better understand their medication switch plan, identify questions to bring to their next appointment, or flag potential concerns before they escalate. With over 22 million AI consultations completed, Doctronic provides a reliable and accessible first step in navigating medication transitions like this one.
Frequently Asked Questions
No exact milligram conversion exists. Liraglutide and dulaglutide differ in molecular structure, half-life, and dosing frequency, so their potencies cannot be directly compared by weight. Clinicians use a conservative starting approach rather than a fixed formula, typically beginning dulaglutide at the lowest available dose and titrating based on individual response.
A formal washout period is generally not required. Because both medications work through the same GLP-1 receptor mechanism, most clinicians advise stopping liraglutide and starting dulaglutide the same day or the following day. Your prescriber can confirm the exact timing based on your specific health history and current regimen.
Some short-term fluctuation in blood glucose is possible during the first one to two weeks of the switch. At therapeutic doses, both medications offer broadly comparable A1C reductions, but individual responses vary. Monitoring blood glucose more frequently right after the switch helps catch any significant changes before your next scheduled provider visit.
Nausea, vomiting, diarrhea, and reduced appetite are the most commonly reported side effects when starting or switching GLP-1 receptor agonists. These symptoms often ease within a few weeks as the body adjusts. Severe or persistent abdominal pain, signs of pancreatitis, or significant blood sugar swings should prompt prompt contact with a clinician.
It is not recommended to switch GLP-1 medications entirely on your own. While Doctronic's AI consultations, which show 99.2% treatment plan alignment with board-certified physicians, can help you understand your switch plan and flag concerns, a licensed prescriber should authorize any medication change, especially for patients with kidney disease, pancreatitis history, or thyroid conditions.
The Bottom Line
Switching from liraglutide to dulaglutide is a clinically common transition that is generally safe, but it requires a personalized approach rather than a fixed conversion formula. Most patients start dulaglutide at 0.75 mg weekly, monitor blood glucose closely for the first two weeks, and titrate gradually based on tolerability and glycemic response. Self-adjusting doses without guidance is not advised. Doctronic offers free AI consultations available 24/7 as an accessible first step for understanding your switch plan before or between provider appointments. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get liraglutide dosing guidance
Chat Now